Form 4: BridgeBio Pharma Executive Sells Shares

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock on April 30, 2026, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Maricel Apuli, Chief Accounting Officer at BridgeBio Pharma, Inc., reported a transaction involving the sale of company stock.
• The transaction, executed on April 30, 2026, involved the disposal of 2,000 shares of common stock.
• The sale price was $71.58 per share, resulting in a total transaction value of $143,160.
• Following this transaction, Apuli beneficially owns 134,115 shares of common stock.
• This sale was conducted under a Rule 10b5-1 trading plan, adopted by the reporting person on September 8, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• The filing is a Form 4, indicating a change in beneficial ownership of securities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the insider sale, although the execution via a 10b5-1 plan mitigates concerns about opportunistic trading.

Negatives

• An executive sold a portion of their holdings in the company.

Risks

• The sale of shares by a key executive could be perceived negatively by the market, potentially impacting investor sentiment.
• While conducted under a 10b5-1 plan, any significant insider selling can raise questions about the executive's confidence in the company's future prospects.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider selling, even when executed under a Rule 10b5-1 plan, is a common event for executives and can be interpreted in various ways by the market. The context of the sale price relative to the current market price and the executive's overall holdings is crucial for a complete assessment.

Stakeholder Impact

• Shareholders: May view the sale as a minor negative signal, though the 10b5-1 plan provides a degree of reassurance.
• Employees: Similar to shareholders, the impact is likely minimal unless the sale is part of a larger trend.
• Creditors: No direct impact expected from this transaction.
• Suppliers: No direct impact expected from this transaction.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, BridgeBio Pharma, BBIO, Beneficial Ownership, Rule 10b5-1, Executive Compensation, Securities Transaction